Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
2004 1
2005 1
2007 2
2010 1
2011 4
2012 3
2013 1
2019 1
2021 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Acute promyelocytic leukemia during pregnancy: report of 3 cases.
Consoli U, Figuera A, Milone G, Meli CR, Guido G, Indelicato F, Moschetti G, Leotta S, Tornello A, Poidomani M, Murgano P, Pinto V, Giustolisi R. Consoli U, et al. Among authors: poidomani m. Int J Hematol. 2004 Jan;79(1):31-6. doi: 10.1007/BF02983530. Int J Hematol. 2004. PMID: 14979475 Review.
Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life Survey.
Markovic U, Romano A, Del Fabro V, Bellofiore C, Bulla A, Parisi MS, Leotta S, Gentile M, Cangialosi C, Vincelli I, Mineo G, Rossi M, Poidomani M, Uccello G, Maugeri C, Mannina D, Innao V, Di Raimondo F, Conticello C. Markovic U, et al. Among authors: poidomani m. Front Oncol. 2021 Mar 5;11:624405. doi: 10.3389/fonc.2021.624405. eCollection 2021. Front Oncol. 2021. PMID: 33763359 Free PMC article.
Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real-Life Survey of the Sicilian Myeloma Network.
Conticello C, Romano A, Del Fabro V, Martino EA, Calafiore V, Sapienza G, Leotta V, Parisi MS, Markovic U, Garibaldi B, Leotta S, Cotzia E, Innao V, Mannina D, Neri S, Musso M, Scalone R, Cangialosi C, Acquaviva F, Cardinale G, Merenda A, Maugeri C, Uccello G, Poidomani M, Longo G, Carlisi M, Tibullo D, Di Raimondo F. Conticello C, et al. Among authors: poidomani m. J Clin Med. 2019 Jun 19;8(6):877. doi: 10.3390/jcm8060877. J Clin Med. 2019. PMID: 31248142 Free PMC article.
Chemosensitivity of nonleukemic clonogenic precursors in AML patients in complete remission: association with CD34(+) mobilization and with disease-free survival.
Milone G, Avola G, Leotta S, Strano A, Camuglia MG, Pinto V, Mercurio S, Poidomani M, Coppoletta S, Di Marco AL, Consoli C, Triolo A, Spadaro A, Privitera A, Ragusa A, Tibullo D, Di Mercurio S. Milone G, et al. Among authors: poidomani m. Exp Hematol. 2012 Jan;40(1):35-47.e2. doi: 10.1016/j.exphem.2011.10.002. Epub 2011 Oct 20. Exp Hematol. 2012. PMID: 22019627 Free article.
Early measurement of CD34+ cells in peripheral blood after cyclophosphamide and granulocyte colony-stimulating factor treatment predicts later CD34+ mobilisation failure and is a possible criterion for guiding "on demand" use of plerixafor.
Milone G, Tripepi G, Martino M, Ancora F, Bartolozzi B, Spadaro A, Nozzoli C, La Fauci A, Amico I, Leotta S, Poidomani M, Irrera G, Iacopino P, Saccardi R, Guidi S, Bosi A. Milone G, et al. Among authors: poidomani m. Blood Transfus. 2013 Jan;11(1):94-101. doi: 10.2450/2012.0004-12. Epub 2012 Oct 10. Blood Transfus. 2013. PMID: 23114516 Free PMC article.
Intermediate dose etoposide plus G-CSF 16 g/kg is more effective than cyclophosphamide 4 g/m(2) plus G-CSF 10 g/kg in PBSC mobilization of lymphoma patients.
Milone G, Leotta S, Battiato K, Murgano P, Mercurio S, Strano A, Poidomani M, Coppoletta S, Mauro E, Avola G, Pinto V, Camuglia MG, Giustolisi R. Milone G, et al. Among authors: poidomani m. Leuk Lymphoma. 2007 Oct;48(10):1950-60. doi: 10.1080/10428190701573240. Leuk Lymphoma. 2007. PMID: 17917963 Clinical Trial.
Efficacy of caspofungin as secondary prophylaxis in patients undergoing allogeneic stem cell transplantation with prior pulmonary and/or systemic fungal infection.
de Fabritiis P, Spagnoli A, Di Bartolomeo P, Locasciulli A, Cudillo L, Milone G, Busca A, Picardi A, Scimè R, Bonini A, Cupelli L, Chiusolo P, Olivieri A, Santarone S, Poidomani M, Fallani S, Novelli A, Majolino I. de Fabritiis P, et al. Among authors: poidomani m. Bone Marrow Transplant. 2007 Aug;40(3):245-9. doi: 10.1038/sj.bmt.1705720. Epub 2007 May 28. Bone Marrow Transplant. 2007. PMID: 17529996 Clinical Trial.
Prognostic value of CD34+ peak in peripheral blood during mobilization in intermediate-risk AML patients treated in first CR by autologous or allogeneic transplantation.
Milone G, Poidomani M, Leotta S, Avola G, Camuglia MG, Privitera A, Consoli C, Mercurio S, Romeo MA, Di Marco A, Di Mercurio S, Spadaro A, Palumbo GA, Tedeschi P. Milone G, et al. Among authors: poidomani m. Bone Marrow Transplant. 2012 Jan;47(1):24-32. doi: 10.1038/bmt.2011.33. Epub 2011 Mar 14. Bone Marrow Transplant. 2012. PMID: 21399670
13 results